Revvity Inc. RVTY
151.11
0.43
0.29%
as of 25 Sep
- Market cap
- $16.8B
- P/E
- 72.0×
Follow RVTY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Revvity Inc. (RVTY) Free cash flow margin
Revvity Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 19.6%, up 1.7 percentage points from fiscal 2025 (17.8%). Over the past ten years it has ranged from 0.36% (fiscal 2023) to 34.6% (fiscal 2021); the current reading is higher than 64% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 17.8% | (1.82) |
| FY2024 | 19.7% | 19.30 |
| FY2023 | 0.36% | (17.58) |
| FY2022 | 17.9% | (16.67) |
| FY2021 | 34.6% | 3.34 |
| FY2020 | 31.3% | 21.47 |
| FY2019 | 9.80% | 0.59 |
| FY2018 | 9.21% | (1.89) |
| FY2017 | 11.1% | (4.97) |
| FY2016 | 16.1% | 3.77 |
Against its own ten years
Low 0.36%
High 34.6%
Ten-year median
16.1%
Current reading's percentile
64
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| MEDP Medpace Holdings, Inc. compare | 25.4% |
| MTD Mettler-Toledo International, Inc. compare | 20.9% |
| RVTY Revvity Inc. | 19.6% |
| DGX Quest Diagnostics Incorporated compare | 11.7% |
| ICLR ICON PLC compare | 10.7% |
| CRL Charles River Laboratories International, Inc. compare | 9.27% |
| LH Labcorp Holdings Inc. compare | 8.16% |
| GH Guardant Health, Inc. compare | −20.4% |
| TWST Twist Bioscience Corporation compare | −22.2% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on RVTY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement